Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-escalation pharmacokinetics and safety of moxifloxacin in tuberculosis
2010-023491-25Phase 4Active
- Sponsor
- University Medical Center Groningen
- Start
- Oct 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of moxifloxacin in Tuberculosis (TB) (3 arms), sponsored by University Medical Center Groningen. Primary endpoints: Pharmacokinetics of moxifloxacin and Safety and tolerability of moxifloxacin dose escalation. Started Oct 2010; status: active.
02
Drugs
moxifloxacin
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on 2010-023491-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023491-25.